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the Morris water maze, contused rats treated with gacyclidine at a dosage of 0.1 mg/kg performed better than their vehicle-treated conspecifics. Rats given gacyclidine at either 0.3 or 0.03 mg/kg performed better than brain-injured controls, but not as well as those treated with 0.1 mg/kg. Counts of surviving neurons in the nucleus basalis magnoceilularis (NBM) and the medial dorsal nucleus (MDN) of the thalamus were used to determine whether gacyclidine treatment attenuated secondary cell death. In both the NBM and the MDN, the counts revealed fewer surviving neurons in untreated contused rats than in gacyclidine-treated rats. Increases in the size and number of microglia and astrocytes were observed in the striatum of gacyclidinetreated contused brains. Although most consequences of MFC contusions were attenuated, we still observed increases in ventricle dilation and thinning of the cortex.
INTRODUCTION
Following traumatic brain injury, excitatory amino acids, such as glutamate, increase to toxic levels and may cause further damage to compromised neurons in the injury zone and to more distal nerve cells (Murphy & Pearce, 1987; Mclntosh, 1994;  Myseros & Bullock, 1995) .
Glutamate, binding to the glutamate recognition site of the NMDA receptor-ionophore complex, permits sodium and calcium ions to enter into the neuron, and if in excess, can initiate hyperexcitation, cytotoxic edema, and eventually cell death (Faden et al., 1989) . Agents that block any of the specific recognition sites of the NMDA receptor-ionophore complex (NMDA antagonists) or the binding sites within the channel (noncompetitive NMDA antagonists) will attenuate calcium influx (Bullock & Fujisawa, 1992; Bullock, 1995) (Panter & Faden, 1992; Golding & Vink, 1995; Okiyama et. al., 1997) .
Some of these agents, however, have been shown to produce negative side effects, such as hallucinations and neuronal vacuolization (Olney et al., 1991; Muir & Lees, 1995) .
A novel, noncompetitive NMDA antagonist, gaeyclidine ( (Mattson & Levin, 1990 ). In this model, the loss of neurons expressing NMDA receptors is associated with impaired learning and memory (Hoffman et. al., 1994) (Kolb et al., 1982; Hoffman et al., 1994; Lindner et al., 1998) . We believe that the MWM can be used to measure both working and/or reference memory, but in our task we were primarily concerned with enhancing performance in brain damaged animals rather than in the specific nature of the task itself. The deficits observed in the MWM following MFC contusions are persistent and amenable to manipulation by drugs and by other procedures we have used in previous work (Stein et al., 1991; Attella et al., 1992; Roof et al., 1994; Janis et al., 1998) . Because treatment with gacyclidine protects against glutamate toxicity in vitro, we reasoned that systemic administration of the drug might effect gliosis, prevent secondary neuronal death, and help reduce the behavioral deficits in the MWM that are seen after medial frontal cortex contusions.
MATERIALS AND METHODS

Subjects
Sixty-four male Sprague-Dawley rats (-90 days old), weighing from 320 to 380 grams each at the time of injury, were used. The animals were housed individually in hanging stainlesssteel cages, with a 12:12 hour reversed light cycle (8:00 to 20:00, dark period, 20:00 to 8:00, light period), and allowed ad libitum access to rat chow and water. Each rat was weighed and handled for 5 min/d during the week before and the week after the surgery.
Surgery
All rats were food deprived for 24 h before surgery. The rats were injected (i.p.) with 0.05 ml atropine sulfate (to reduce respiratory congestion), anesthetized with sodium pentobarbital (Nembutal, 50 mg/kg) and mounted in a stereo-taxic device. A midline incision was made in the scalp, the fascia was retracted, and the cranium was exposed, using aseptic technique. At this point, all sham-operated controls were sutured and prepared for the injection of gacyclidine or vehicle (sterile water). Details of the contusion procedure have been reported previously (Hoffman et. al., 1994 ), but will be briefly outlined here. The rats that were destined to receive cortical contusions of the medial frontal cortex first underwent a 6-mm-diameter craniotomy (centered at 3.0 mm anterior to bregma).
After removal of the bone, the tip of the impactor was moved to AP: 3.0; ML: 0.0 (Paxinos & Watson, 1982) Morris water maze. After 7 days of postoperative recovery, the animals began training in the MWM (Morris, 1981 , Hoffman et al., 1994 
Image analysis
Anatomical analysis was aided by a video microscopy system. The images were captured using a single-chip, analog color video camera. Once captured and saved in tiff format on the PC, the image was cropped using Adobe Photo Shop TM and imported into UTHSCSA ImageTool (v. 1.27) for further quantitative morphometric assessment. All investigators were blind as to group assignment until the completion ofthe study.
Lesion reconstruction. Sections at three levels (3.5, 2.5, 1.5 mm) anterior to bregma were captured at a magnification of 1.67x. The lesion cavity was traced and measured using the ImageTool software package. The area of the three levels of lesion cavities was quantified and summed to determine a mean area percentage. The scores were then used to compute a mean area ratio score (area of the lesion/area of lesion + total area of the slice). The ratios were then used to determine the differences, if any, in lesion cavity size between treatment levels.
Ventricle dilation was measured on thioninstained sections at the level of 1.0 mm anterior to bregrna. The area of each ventricle was traced and quantified using the ImageTool software package. The area scores were used to compute a mean area ratio score (area of the ventricles/area of ventricles + total area of the slice). The ratios were used to calculate differences in ventricle size between lesion and treatment levels.
Cortical thickness. (Dekker, et. al., 1991 (Leonard, 1969 
RESULTS
Activity measurements
Analyses of the activity levels of the rats were made on the first, third, and fifth postoperative days and again on the twenty-second and twenty-fourth postoperative days (Fig. 1) The animals treated with 0.1 mg/kg of gacyclidine performed significantly better than the lesion-vehicle group, both early and late in training. This analysis showed that regardless of dose, the drug improved the performance of the injured rats (Fig. 2a) . Additionally, injured rats given 0.1 mg/kg of gacyclidine performed (Fig. 3) . When comparing the distance traveled by the rats, we found that the performance of gacyclidinetreated rats was significantly better than that of rats in the lesion-vehicle group by the final three days of testing (12<0.05), although no treatment group reached the level of performance of intact rats. On the second, eighth, and tenth days of training, rats treated with 0.1 mg/kg of gacyclidine performed better than those in the other treatment groups (Fig. 3a) . When (Fig. 6b ).
GAFP immunoreactivity
We have previously shown (Fulop, et. al., 1992) 
Microglial activation
The pattern of microglia activation was similar to that of the astrocytes, but in addition to hypertrophy, we also observed a large increase in activated microglia. The number of activated microglia was significantly increased in lesion animals in comparison with those in uninjured controls (Fig. 7c), [F(1,32) [F(1,32) 19.48, p<0 .001 than did their vehicle treated conspecifics. The microglia (Fig. 8b,   8d , 8f) in the striatum of rats given 0.1 mg/kg of gacyclidine were twice as large (0.604+0.28 tm vs. 0.363+0.14 tm 2) as those in their vehicletreated counterparts [t(45)= 5.05, p<0.001] (Fig.  7d ). 
DISCUSSION
Bilateral contusion of the medial frontal cortex is a highly effective and replicable model to study the behavioral, anatomical, and physiological changes that occur after traumatic brain injury. The behavioral deficits caused by this type of brain injury are severe and long lasting (Hoffman, et. al., 1994) . Using this injury model to study recovery of function, we have shown that gacyclidine, a novel, noncompetitive NMDA antagonist, improves behavioral and alters anatomic outcomes following medial frontal cortex contusions in adult rats.
All three doses of the drug; 0.01, 0.1, and 0.3 mg/kg (i.v.), administered 10 min after the contusion injury, enhanced the performance of the animals in the water maze. The significantly better performance of rats given the 0.1 mg/kg dose of gacyclidine than of those given the 0.01 and 0.3 mg/kg doses reveals a U-shaped or sigmoidal function of the drug's effect; a finding that is not uncommon in such studies. Despite the observation of faster behavioral recovery, we noted that none of the gacyclidine-treated rats reached a level of performance equivalent to that of the intact controls. Gacyclidine also had no influence on the animals' general activity levels during the course of the experiment. The hypoactivity of the contused rats, seen on the first day after surgery, disappeared in all lesion groups by the third postoperative day, when performance was equivalent to that of intact controls. (Jenkins, et al., 1988 , Mclntosh, et al., 1990 , Smith, et al., 1993 .
Glial cell activation
Along with cortical thinning, behavioral improvement and neuronal sparing in the nucleus basalis in gacyclidine-treated brain-damaged rats was paralleled by an increased activation of both astrocytes and microglia. The number of GFAPpositive astrocytes was higher in sham-operated than in all injured groups, both at the site of the injury and in areas distal to the lesions. We also observed that gacyclidine had a profound effect upon the size of the astrocytes and the number of microglia. Astrocytes in the striatum of animals treated with 0.1 mg/kg of gacyclidine were more than three times larger than astrocytes measured in vehicle-treated rats. In addition to their hypertrophy, activated microglial cells also showed increased proliferation when treated with the 0.1 mg/kg dose of gacyclidine.
Whereas the cellular hypertrophy observed in both astrocytes and microglia (Fig. 6) could be a sign of pathology (swelling caused by cytotoxic edema), it might also be an indication of the increased synthetic and absorption capacity of the cells (Hanker, G., 1980; Rudge, et al., 1985; Assouline, et al., 1987) . Both types of glial cells are reported to be equipped with NMDA receptors (Cull-Candy, 1995; Conti et al., 1996; , although microglial cells are believed to be the primary glial cells capable of activation (or inhibition) by altering their NMDA receptors (Giulian et al., 1994) . Activated micro-glial cells, apart from their increased phagocytic capacity, release different types of cytokines, which in turn will activate astrocytes (Waltz, 1989; Wilkin et al., 1991; Balasingam et al., 1994) . Activated astrocytes are known to synthesize and release a large variety of neurotrophic factors, which in turn, can increase neuronal survival (Martin, 1992;  McGeer & McGeer, 1995; Vaca & Wendt, 1992 (Haglid et al., 1991; Fox et al., 1996; Nordqvist et al., 1997) including the activation of subcortical structures that are typically depressed by trauma, via the stimulation of dopaminergic neurons. Some of these studies suggest the possibility of a direct, neuroprotective capacity of NMDA antagonists (Sauer et al., 1988) , or that they may also work indirectly by activating glial cells (Pearce, 1991; Giulian et. al., 1994) . Recently, Obrenovitch & Urenjak (1997) (Meyer et al., 1990; Stevens & Yaks, 1990; Muir & Lees, 1995; Miller et al., 1996; Maione et al., 1998) . Furthermore, these type of drugs influence the body's water balance (Espanol et al., 1994; Kuroda et al., 1994; Sluka et al., 1994) ; hormone secretion and release (Arslan et al., 1992; Estienne et al., 1996; Pinilla et al., 1996) , as well as the respiratory drive and oxygen consumption (Bissonnette et al., 1997; Lu et al., 1997 
